CPEB4通过上调PFKFB3诱导糖酵解并激活肝星状细胞促进肝纤维化
该研究探讨肝星状细胞(HSC)活化中糖酵解的作用及PFKFB3调控机制。在小鼠HSC、人LX2细胞、肝纤维化动物模型及人肝硬化组织中,发现PFKFB3蛋白上调与糖酵解增强是HSC活化的早期持续事件;CPEB4通过结合PFKFB3 mRNA的3'非翻译区胞质多聚腺苷酸化元件促进其表达。抑制或敲低PFKFB3/CPEB4可减轻HSC活化与肝纤维化。
要点
- PFKFB3上调与糖酵解增强是HSC活化的早期持续事件
- CPEB4通过结合PFKFB3 mRNA的3'UTR促进其蛋白表达
- 抑制PFKFB3或敲除CPEB4可减轻小鼠肝纤维化
核心结论
- 人和啮齿类动物纤维化肝组织中PFKFB3和糖酵解水平升高,为HSC活化所必需。
- CPEB4通过结合PFKFB3 mRNA的3'非翻译区胞质多聚腺苷酸化元件上调其表达。
- 抑制或敲低CPEB4或PFKFB3可阻止小鼠HSC活化和肝纤维化。
研究设计与样本
- 研究使用原代小鼠HSC、人LX2 HSC、人肝硬化肝组织、胆管结扎(BDL)或四氯化碳诱导的肝纤维化大鼠和小鼠,以及CPEB4敲除小鼠。
- 通过小分子PFKFB3拮抗剂3PO抑制细胞和小鼠糖酵解,并用siRNA敲低PFKFB3或CPEB4。
主要发现
- HSC活化过程中PFKFB3蛋白上调和糖酵解增强是早期且持续的事件,并伴随纤维化标志物表达增加。
- 3PO处理或敲低PFKFB3可降低HSC活化和增殖。
- BDL术后小鼠肝PFKFB3升高,术后立即注射3PO可预防HSC活化并减轻肝纤维化严重程度(与溶媒对照相比)。
- 人纤维化肝组织中PFKFB3蛋白水平高于非纤维化肝组织。
- CPEB4敲除小鼠在BDL或四氯化碳处理后肝脏PFKFB3和纤维化程度低于野生型小鼠。
临床怎么用
- 靶向CPEB4-PFKFB3轴可能成为抗肝纤维化的治疗策略。
- PFKFB3抑制剂3PO在动物模型中显示可预防HSC活化和纤维化进展。
局限性
- 研究主要基于动物模型和细胞实验,尚未在人体中进行治疗验证。
- 原文未报告3PO的剂量、给药方案及长期安全性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: We investigated mechanisms of hepatic stellate cell (HSC) activation, which contributes to liver fibrogenesis. We aimed to determine whether activated HSCs increase glycolysis, which is regulated by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3), and whether this pathway might serve as a therapeutic target. METHODS: We performed studies with primary mouse HSCs, human LX2 HSCs, human cirrhotic liver tissues, rats and mice with liver fibrosis (due to bile duct ligation [BDL] or administration of carbon tetrachloride), and CPEB4-knockout mice. Glycolysis was inhibited in cells and mice by administration of a small molecule antagonist of PFKFB3 (3-[3-pyridinyl]-1-[4-pyridinyl]-2-propen-1-one [3PO]). Cells were transfected with small interfering RNAs that knock down PFKFB3 or CPEB4. RESULTS: Up-regulation of PFKFB3 protein and increased glycolysis were early and sustained events during HSC activation and accompanied by increased expression of markers of fibrogenesis; incubation of HSCs with 3PO or knockdown of PFKFB3 reduced their activation and proliferation. Mice with liver fibrosis after BDL had increased hepatic PFKFB3; injection of 3PO immediately after the surgery prevented HSC activation and reduced the severity of liver fibrosis compared with mice given vehicle. Levels of PFKFB3 protein were increased in fibrotic liver tissues from patients compared with non-fibrotic liver. Up-regulation of PFKFB3 in activated HSCs did not occur via increased transcription, but instead via binding of CPEB4 to cytoplasmic polyadenylation elements within the 3'-untranslated regions of PFKFB3 messenger RNA. Knockdown of CPEB4 in LX2 HSCs prevented PFKFB3 overexpression and cell activation. Livers from CPEB4-knockout had decreased PFKFB3 and fibrosis after BDL or administration of carbon tetrachloride compared with wild-type mice. CONCLUSIONS: Fibrotic liver tissues from patients and rodents (mice and rats) have increased levels of PFKFB3 and glycolysis, which are essential for activation of HSCs. Increased expression of PFKFB3 is mediated by binding of CPEB4 to its untranslated messenger RNA. Inhibition or knockdown of CPEB4 or PFKFB3 prevents HSC activation and fibrogenesis in livers of mice.
引用
- Mejias M, Gallego J, Naranjo-Suarez S, et al. CPEB4 Increases Expression of PFKFB3 to Induce Glycolysis and Activate Mouse and Human Hepatic Stellate Cells, Promoting Liver Fibrosis. Gastroenterology. 2020. PMID: 32169429. doi:10.1053/j.gastro.2020.03.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。